ALVAC-CEA B7.1

Drug Profile

ALVAC-CEA B7.1

Alternative Names: CEA vaccine; TBC CEA

Latest Information Update: 27 Nov 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Cancer Institute (USA); Therion Biologics
  • Developer National Cancer Institute (USA); sanofi-aventis; Therion Biologics
  • Class
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 18 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 11 Feb 2003 Phase-I clinical trials in stage III Colorectal cancer in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top